Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

BACKGROUND: Camrelizumab (a PD-1 inhibitor) has been used as a potential therapy in unresectable advanced esophageal squamous cell carcinoma (ESCC) along with adjuvant treatment in locally advanced ESCC, exhibiting an acceptable efficacy and safety profile. This pilot study was designed to further i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Peng, Zhou, Xiao, Yang, Xuefeng, Wang, Yuefeng, Sun, Tao, Feng, Shiying, Ma, Xianyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609728/
https://www.ncbi.nlm.nih.gov/pubmed/34809658
http://dx.doi.org/10.1186/s12957-021-02446-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609728/
https://www.ncbi.nlm.nih.gov/pubmed/34809658
http://dx.doi.org/10.1186/s12957-021-02446-5

Ejemplares similares